Alithea Genomics

About Alithea Genomics

Alithea Genomics provides extraction‑free, massively multiplexed RNA‑sequencing kits and services for bulk, single‑cell, organoid, plant, and blood samples. Their Mercurius platform enables up to 384 library preparations in a single tube, supporting 3′, targeted, and full‑length transcriptome readouts. The solutions accelerate drug screening, biomarker discovery, and large‑scale gene expression studies while reducing reagent use and labor.

<problem> Traditional RNA sequencing methods can be expensive and have limitations in sample throughput, which can hinder biomedical research and drug discovery efforts. These limitations can make it difficult for pharmaceutical companies and research institutions to conduct large-scale gene expression studies in a cost-effective manner. </problem> <solution> Alithea Genomics offers transcriptomics solutions designed to optimize the costs and increase the throughput of RNA sequencing. The company's Mercurius™ DRUG-seq and BRB-seq technologies enable massive sample multiplexing, processing up to 384 library preps in a single tube, and can eliminate the need for RNA extraction. These solutions are compatible with diverse sample types, including purified RNA, cells, organoids, FFPE tissues, and blood samples, and support various sequencing options, from 3' to targeted and full-length RNA sequencing. Alithea Genomics provides both library prep kits and sequencing services, offering a streamlined workflow from sample to data in as little as two weeks. </solution> <features> - Mercurius™ DRUG-seq kits for extraction-free RNA sequencing directly from cell, organoid, and tissue lysates - Mercurius™ BRB-seq kits for bulk RNA sequencing from purified RNA samples - Massive sample multiplexing, enabling up to 384 library preps in a single tube - Compatibility with diverse sample types, including cells, organoids, FFPE tissues, and blood samples - Support for various sequencing options, including 3' mRNA-seq, full-length mRNA-seq, and targeted mRNA-seq - Custom-developed panels for targeted RNA sequencing, with up to 100 targets - Cell Lysis Modules for direct lysis from frozen cells, skipping RNA extraction steps - Gb-to-M reads converter and DNA µg-to-pmol converter tools </features> <target_audience> Alithea Genomics serves pharmaceutical companies, research institutions, and crop science organizations seeking cost-effective, high-throughput RNA sequencing solutions for drug screening, biomarker discovery, and fundamental research. </target_audience> <revenue_model> Alithea Genomics generates revenue through the sale of library prep kits and by offering RNA sequencing services. </revenue_model>

What does Alithea Genomics do?

Alithea Genomics provides extraction‑free, massively multiplexed RNA‑sequencing kits and services for bulk, single‑cell, organoid, plant, and blood samples. Their Mercurius platform enables up to 384 library preparations in a single tube, supporting 3′, targeted, and full‑length transcriptome readouts. The solutions accelerate drug screening, biomarker discovery, and large‑scale gene expression studies while reducing reagent use and labor.

When was Alithea Genomics founded?

Alithea Genomics was founded in 2020.

How much funding has Alithea Genomics raised?

Alithea Genomics has raised $4.4M.

Founded
2020
Funding
$4.4M
Employees
30 employees
Major Investors
Technology Fund

Alithea Genomics

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Alithea Genomics provides extraction‑free, massively multiplexed RNA‑sequencing kits and services for bulk, single‑cell, organoid, plant, and blood samples. Their Mercurius platform enables up to 384 library preparations in a single tube, supporting 3′, targeted, and full‑length transcriptome readouts. The solutions accelerate drug screening, biomarker discovery, and large‑scale gene expression studies while reducing reagent use and labor.

alitheagenomics.com3K+
Founded 2020

Funding

No specific funding rounds found.

Total Funding

$4.4M

Backed by

Technology Fund

Team (30+)

No team information available.

Company Description

Problem

Traditional RNA sequencing methods can be expensive and have limitations in sample throughput, which can hinder biomedical research and drug discovery efforts. These limitations can make it difficult for pharmaceutical companies and research institutions to conduct large-scale gene expression studies in a cost-effective manner.

Solution

Alithea Genomics offers transcriptomics solutions designed to optimize the costs and increase the throughput of RNA sequencing. The company's Mercurius™ DRUG-seq and BRB-seq technologies enable massive sample multiplexing, processing up to 384 library preps in a single tube, and can eliminate the need for RNA extraction. These solutions are compatible with diverse sample types, including purified RNA, cells, organoids, FFPE tissues, and blood samples, and support various sequencing options, from 3' to targeted and full-length RNA sequencing. Alithea Genomics provides both library prep kits and sequencing services, offering a streamlined workflow from sample to data in as little as two weeks.

Features

Mercurius™ DRUG-seq kits for extraction-free RNA sequencing directly from cell, organoid, and tissue lysates

Mercurius™ BRB-seq kits for bulk RNA sequencing from purified RNA samples

Massive sample multiplexing, enabling up to 384 library preps in a single tube

Compatibility with diverse sample types, including cells, organoids, FFPE tissues, and blood samples

Support for various sequencing options, including 3' mRNA-seq, full-length mRNA-seq, and targeted mRNA-seq

Custom-developed panels for targeted RNA sequencing, with up to 100 targets

Cell Lysis Modules for direct lysis from frozen cells, skipping RNA extraction steps

Gb-to-M reads converter and DNA µg-to-pmol converter tools

Target Audience

Alithea Genomics serves pharmaceutical companies, research institutions, and crop science organizations seeking cost-effective, high-throughput RNA sequencing solutions for drug screening, biomarker discovery, and fundamental research.

Revenue Model

Alithea Genomics generates revenue through the sale of library prep kits and by offering RNA sequencing services.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.